PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$32.69 USD
-1.16 (-3.43%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $32.71 +0.02 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
PTCT 32.69 -1.16(-3.43%)
Will PTCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PTCT
Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
PTCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
Other News for PTCT
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)
Leerink Partners Reaffirms Their Hold Rating on PTC Therapeutics (PTCT)
Truist healthcare analyst holds an analyst/industry conference call
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA
PTC Therapeutics submits sepiapterin NDA to U.S. FDA